Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable
2 ESMO: Amgen's KRAS drug tackles 32% of lung cancers—and this is just the beginning
3 Sotorasib shows anticancer activity in KRAS G12C-mutated NSCLC
4 KRAS 117N Positive Rosai-Dorfman with Atypical Features
5 CNIO researchers develop an effective strategy against KRAS mutant lung tumors in mice
6 Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors | Small Molecules | News Channels
7 Dr. Pant on Targeting KRAS Mutations in Metastatic Solid Tumors
8 PNAS Papers on KRAS-Mutated Lung Cancer, p53-Related Transcriptional Features, More
9 Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
10 Stronger together? Boehringer and Mirati team to put first KRAS-KRAS combo in the clinic
11 Cardiff Oncology Presents Data at ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
12 As It Unfolds
13 Molecular Profiling in Metastatic Colorectal Cancer
14 Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue
15 Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
16 Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity
17 Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
18 Europe’s Biggest Cancer Research Conference Happens This Weekend. What to Watch.
19 Caris Life Sciences to Present New Ovarian Cancer Research at ESMO Virtual Congress 2020
20 Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit
21 Cardiff Oncology : Investor Presentation
22 Drs. Kathryn Arbour, Carl Gay, and Sean Pitroda receive prestigious LUNGevity 2020 Career Development Awards
23 Boehringer, Mirati Therapeutics Enter Clinical Collaboration
24 Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
25 Special Report: Next-gen kinase inhibitors march toward market—and spur billions in M&A
26 mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population
27 Monte Rosa raises $96M Series B for drug development platform technology
28 Slicing the pie: Personalized medicine changing pancreatic cancer outcomes
29 Why KRAS Inhibitors for Lung Cancer Stop Working (and What Can Be Done about It)
30 AACR: Early Trovagene data offer hope for KRAS-mutant colon cancer
31 STAT Virtual Event: The ESMO Recap, Live!
32 Eli Lilly crashes out of KRAS race as toxicity sees it ditch phase 1 effort
33 Assessing the Actionability of KRAS Mutations in NSCLC
34 KRAS Inhibitors Pipeline Drugs: Opportunity Assessments, Market Dynamics and Pipeline Analysis H2 2020
35 Anticancer Drug Team-Ups Show Promise. Lilly, J&J, Amgen, and Gilead Stand to Gain.
36 A sadly familiar disappointment in Alzheimer's research
37 Targeting KRAS Mutations in Advanced NSCLC
38 Predicting resistance to KRAS inhibitors | Science Signaling
39 Targeting KRAS-Mutant Tumors With Indirect Targeting of Related Pathways Yields Hope in Solid Tumors
40 Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC
41 The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
42 Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
43 KRAS Tests
44 ASCO: Amgen's KRAS drug shows 'modest' efficacy beyond NSCLC
45 Zagreb bourse drops Kras, Atlantska Plovidba from blue-chip index, adds Koncar, Arena Hospitality Group
46 Watch out, Amgen and Mirati. Boehringer's pan-KRAS inhibitor enters cancer clinical trials
47 Clinical Activity of RAF/MEK + FAK Combo in KRAS-Mutant... : Oncology Times
48 Caris Life Sciences Showcases Data on KRAS Mutations in Patients With Non-Small Cell Lung and Pancreatic Cancer at ASCO20 Virtual Scientific Program
49 Small molecule combats cancer-causing KRAS protein at last
50 Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
51 AACR 2020 – Verastem reveals the logic behind its Kras deal
52 Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
53 Relay Therapeutics Uses Protein Motion Simulation to Develop Highly Selective Precision Cancer Drugs
54 Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell | CMAR
55 Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response | Small Molecules | News Channels
56 Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug
57 KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers
58 Notorious KRAS: Taking down cancer researchers' biggest foe
59 Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients
60 At ASCO, AstraZeneca does a star turn and KRAS fizzles
61 AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors
62 Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex
63 Fortress joins KRAS race through Columbia University deal
64 Overcoming KRAS-driven lung cancer resistance to drugs | Result in Brief | H2020 | CORDIS | European Commission
65 Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
66 A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
67 Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor
68 Verastem pens KRAS-focused drug licensing deal with Chugai
69 Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLC
70 Revolution Medicines Doses First Patient in Study of SHP2 Inhibitor With Amgen's KRAS Inhibitor
71 Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
72 Key Results Areas Identified To Address Hunger In PH
73 Onvasertib: Confirmed Tumor Regression + Clinical Benefit in KRAS-Mutated mCRC
74 Revolution files for $100M IPO to advance KRAS candidates
75 KRAS Tests (In Vitro Diagnostics)
76 Elicio Therapeutics and NCI study ELI-002 mutant KRAS targeting mechanism
77 Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
78 RAF-MEK Inhibitor/Defactinib Combo Is Active in KRAS-Mutant Cancers
79 Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout
80 KRAS G12C metastatic colorectal cancer: Specific features of a new emerging target population
81 Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
82 Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC
83 Onvansertib Triplet Shows Promise in KRAS-Mutant Metastatic Colorectal Cancer
84 FDA Grants Fast Track Designation to Onvansertib for KRAS+ mCRC Treatment
85 Ginsburg v. cancer was a 'remarkable fight': RBG battled five bouts of cancer over two decades
86 Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors
87 Turning Point Therapeutics' Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models
88 KRAS drug developers offer early data on new classes of small molecules
89 Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
90 Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy
91 Mirati's KRAS Inhibitor Promising in Early-Stage Trial of Solid Tumors
92 Two new drugs finally hit 'undruggable' cancer target, providing hope for treatments
93 RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
94 Plasma giant Grifols to buy Alkahest, a startup targeting blood proteins
95 Pembrolizumab Benefit Not Altered by KRAS Status in Nonsquamous NSCLC
96 Exosome-Based Treatment Targeting KRAS G12D-Mutated Pancreatic Cancer to Enter Human Studies Next Month
97 Trovagene tries roundabout approach to colorectal cancer with 'undruggable' mutation
98 Exploratory Analysis Shows Significant OS Results from Keytruda in KRAS Mutations
99 Onconova to Enroll Patients With KRAS-Mutated Lung Cancer in Phase I/II Rigosertib Trials
100 A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer